Shedding of Infectious SARS-CoV-2 DespiteVaccination

- 3 Kasen K. Riemersma, DVM, PhD1; Luis A. Haddock III, MS1; Nancy A. Wilson, PhD2; Nicholas Minor, BS2; Jens
- 4 Eickhoff, PhD³; Brittany E. Grogan, MPH⁴; Amanda Kita-Yarbro, MPH⁴; Peter J. Halfmann, PhD¹; Hannah E.
- 5 Segaloff, PhD⁵; Anna Kocharian, MS6; Kelsey R. Florek, MPH, PhD7; Ryan Westergaard, MD, PhD8; Allen
- 6 Bateman, PhD⁷; Gunnar E. Jeppson, BS⁹; Yoshihiro Kawaoka, DVM, PhD¹; David H. O'Connor, PhD²[^]; Thomas
- 7 C. Friedrich, PhD1[^]; Katarina M. Grande, MPH4[^]
- ⁹ Department of Pathobiological Sciences, University of Wisconsin School of Veterinary Medicine, Madison, WI,
- 10 USA

8

21

- ¹¹ ²Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public
- 12 Health, Madison, WI, USA
- ³Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison,
- 14 WI, USA
- 15 4Public Health Madison & Dane County, Madison, WI, USA
- ⁵Epidemic Intelligence Service, CDC, Atlanta, GA, USA
- 17 6Wisconsin Department of Health Services, Madison, WI, USA
- ⁷Wisconsin State Laboratory of Hygiene, Madison, WI, USA
- 19 *Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
- ⁹Exact Sciences, Madison, WI, USA
- ²² These authors contributed equally.
- 23 Correspondence can be addressed to:
- 24 Katarina Grande, KGrande@publichealthmdc.com
- 25 Short title: SARS-CoV-2 RNA levels in breakthrough and unvaccinated Delta infections

28 Abstract

40

The SARS-CoV-2 Delta Variant of Concern is highly transmissible and contains mutations that confer partial im-29 mune escape. The emergence of Delta in North America caused the first surge in COVID-19 cases after SARS-30 CoV-2 vaccines became widely available. To determine whether individuals infected despite vaccination might 31 be capable of transmitting SARS-CoV-2, we compared RT-PCR cycle threshold (Ct) data from 20,431 test-pos-32 itive anterior nasal swab specimens from fully vaccinated (n = 9,347) or unvaccinated (n=11,084) individuals 33 tested at a single commercial laboratory during the interval 28 June - 1 December 2021 when Delta variants 34 were predominant. We observed no significant effect of vaccine status alone on Ct value, nor when controlling 35 for vaccine product or sex. Testing a subset of low-Ct (<25) samples, we detected infectious virus at similar rates, 36 and at similar titers, in specimens from vaccinated and unvaccinated individuals. These data indicate that vac-37 cinated individuals infected with Delta variants are capable of shedding infectious SARS-CoV-2 and could play 38 a role in spreading COVID-19. 39

41 Main text

12 Introduction

The SARS-CoV-2 Delta variant was initially characterized in March 2021 and was associated with increased 43 infection incidence in North America beginning in the summer of 2021. In Wisconsin, Delta-lineage viruses were 44 first detected on 12 April 2021, and within 10 weeks accounted for more than 90% of sequenced viruses. Delta 45 viruses were highly transmissible and contained mutations that confer partial immune escape. The "surge" in 46 cases attributable to Delta-lineage viruses represented the first substantial increase in SARS-CoV-2 infection 47 incidence after vaccines had become widely available in the United States. By July 2021, SARS-CoV-2 infec-48 tion incidence was low in the United States (https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/ 49 past-reports/05212021.html#print) [1], and national and local public health agencies were loosening require-50 ments for face coverings and other non-pharmaceutical interventions to reduce virus transmission [1–3]. A key 51 question in developing these policies was whether persons infected with SARS-CoV-2 despite vaccination could 52 transmit infection to others. 53

54 55

By late July 2021, outbreak investigations suggested that vaccinated persons who became infected could spread Delta-lineage SARS-CoV-2 [4,5]. To determine whether individuals with vaccine breakthrough infections could 56 shed Delta viruses at levels consistent with potential transmission, we compared the SARS-CoV-2 RNA burden 57 in nasal swab specimens from vaccinated and unvaccinated individuals tested at a single commercial laboratory. 58 We also attempted virus isolation and determined infectious viral titers from a subset of samples from vaccinat-59 ed and unvaccinated individuals. We focus here on samples collected between 28 June 2021 and 1 December 60 2021, an interval that spans the time when Delta virus first accounted for at least 90% of sequenced specimens 61 in Wisconsin and the first detection of an Omicron sequence on 4 December 2021 (https://www.dhs.wisconsin. 62 gov/news/releases/120421.htm). 63

4 Methods

65 Study design

To estimate nasal viral RNA burden, we compared RT-PCR cycle threshold (Ct) data from 30,101 test-positive 66 anterior nasal swab specimens from fully vaccinated (n =9,347) or unvaccinated (n = 11,084) individuals. Sam-67 ples were collected using the same collection kits from multiple clinic locations. All viral RNA extraction and 68 RT-PCR was performed at a single commercial testing provider (Exact Sciences, Madison, WI) using the same 69 protocol. Because this is a cross-sectional study analyzing specimens submitted for clinical testing, we are only 70 able to analyze a single timepoint from most individuals in our cohort. The estimated prevalence of Delta in Wisconsin was 60% at the start of the study on 28 June 2021, reached 95% by 23 July 2021, and remained at or 72 above 95% until 12 December, 2021 (outbreak.info). The cutoff date was chosen to exclude samples containing 73 the Omicron variant, which was first detected in Wisconsin 4 December 2021. 74

⁷⁶ RT-PCR assay

96

102

111

The Flu-SC2 Multiplex Assay (https://www.cdc.gov/coronavirus/2019-ncov/lab/multiplex.html) as implemented 77 by Exact Sciences was used to determine Ct values. This RT-PCR assay can simultaneously detect nucleic acid 78 from SARS-CoV-2, as well as Influenza A and B from anterior nasal swabs, RNA extraction was conducted us-79 ing Exact Sciences Corporation's proprietary extraction procedure on the Hamilton STARlet liquid handler. The 80 oligonucleotide primers and probe for detection of SARS-CoV-2 were selected from an evolutionarily conserved 81 region of the 3' terminus of SARS-CoV-2 genome and also cover part of the 3'-terminal portion of the nucleocap-82 sid (N) gene. RNA isolated from anterior nasal swab specimens was reverse transcribed into cDNA and amplified 83 using the ThermoFisher TagPath 1-Step RT-qPCR Master Mix and Applied Biosystems 7500 Fast Dx Real-Time 84 PCR Instrument with SDS version 1.4.1 software. Controls included a no-template control, a positive extraction 85 control containing human RNAse P, and an internal control for RNAse P.

Defining vaccination status

Individuals were considered fully vaccinated at the time of testing if vaccine registry or self-reported data indicated receiving a final vaccine dose at least 14 days prior to submitting the specimen that tested positive for SARS-CoV-2 and was used in our analysis. We used validated public health vaccine registries for the State of Wisconsin where possible. Self-reported vaccination status was included with sample metadata submitted by testing providers to the Exact Sciences laboratory; when individuals' vaccination status was not available in public health databases, we used self-report data to determine status. Comparing self-reporting to data from vaccine registries determined that under-reporting of full vaccination status was more common than over-reporting (Supplemental Figure 1).

Specimens from individuals who were partially vaccinated (i.e., had not received a complete vaccine series, were tested <14 days after the final dose, or those whose vaccination dates were after the sample collection date) were excluded. We also excluded 430 samples from individuals who received a booster vaccine dose prior to the sample collection date, since these individuals represented a small fraction of the total number of available samples and booster effects could confound our analyses.

Virus isolation and plaque assay

With an initial set of specimens with Ct values <25, we assessed the presence of infectious virus by inoculating 103 residual specimens onto a monolayer of Vero E6/TMPRSS2 cells and monitoring for the presence of cytopathic 104 effects over 5 days. Specimens were selected by N1 Ct-matching between fully vaccinated and unvaccinated 105 persons. Specimens from individuals with unknown vaccine status were excluded from this assay. With a sec-106 ond set of samples, we determined virus titer, expressed as plaque-forming units (PFU) per ml specimen, by 107 using a 10-fold dilution series along with undiluted samples to infect a monolayer of Vero E6/TMPRSS2 cells 108 (100 µl per well) for 30 minutes at 37°C. The cells were washed once to remove unbound virus, then overlaid 109 with 1% methylcellulose for four days at which time plaques were counted. 110

Statistical analysis

112 We used analysis of variance (ANOVA) to evaluate how Ct values varied between age groups, sexes, and by

vaccine product, as well as two-way interactions between these factors. Raw Ct values were not normally dis-tributed, so we log-transformed all Ct values prior to ANOVA, and confirmed normality by plotting residuals and normal probability (Supplemental Figure 2). We report least square means along with the corresponding 95% confidence intervals (CIs). Tukey's Honestly Significant Difference Method (HSD) was used to control the type error when conducting multiple comparisons between groups. Because our dataset included individuals with varying amounts of time between vaccination and SARS-CoV-2 infection, it is possible that waning levels of immunity could impact susceptibility to infection and/or viral loads after vaccination. To determine whether there was a relationship between time since vaccination and Ct values in infected persons, we conducted additional regression analyses that included months since completion of vaccination as a vaccine manufacturer-specific continuous predictor variable. Months since completion of vaccination was defined as the number of days since completion divided by 30.44, the average number of days per month.

In order to quantify and interpret differences between groups, we calculated standardized differences (Cohen's effect size d), defined as the mean differences between groups divided by the pooled standard deviations. Effect sizes of d<0.2 were considered to indicate either no difference or a negligible difference between populations. An effect size of 0.2 to 0.5 indicated a small difference, 0.5 to 0.8 was a moderate difference, and >0.8 was a large difference. The proportions of subjects with Ct values <25 were compared between groups using a chi-square test.

The results of the primary comparisons were confirmed by conducting nonparametric analyses. Specifically, the nonparametric Wilcoxon rank sum test was used to conduct comparisons between Ct values between the two groups, and the nonparametric Kruskal-Wallis test was used to conduct the comparisons of Ct values between more than two groups. Statistical analyses were conducted using SAS software (SAS Institute, Cary NC), version 9,4, figures were plotted using the R package ggplot2 [6] or from Prism version 9.3.1.

Results

139

140

141

142

143

144

146

147

148

149

150

151

152

153

154

156

157 158

159

167

168

169

170

171

172

173

Individuals infected with SARS-CoV-2 despite vaccination have low Ct values.

SARS-CoV-2 RT-PCR Ct values <25 had previously been associated with shedding of infectious SARS-CoV-2 [7,8]. We observed Ct values <25 in 6,253 of 9,347 fully vaccinated (67%) and 6,739 of 11,084 (61%) unvaccinated individuals (Figure 1A). Because of the very large number of samples, very small differences in outcome variables may nonetheless reach statistical significance when using p values with a traditional alpha set to 0.05. That is, we may find small differences between groups that are statistically significant (p < 0.05), but have a negligible effect (d < 0.2). In order to quantify the magnitude of differences between groups, we calculated stan-145 dardized differences (Cohen's effect size d), defined as the mean differences between the groups divided by the pooled standard deviations. A value of d < 0.2 indicates negligible effects of the analyzed variables on the outcome variable. Here we report values for both p and d for completeness. We observed no significant effect of vaccination status on Ct values in infected persons (Cohen's d=0.14, p<0.0001; **Table 1**). Low Ct values were detected in vaccinated people whether or not they reported symptoms at the time of testing (Figure 1B), with Ct values <25 detected in 65% (95% CI:63-66%) of unvaccinated symptomatic individuals and in 70% (95% CI:69-71%) of fully vaccinated symptomatic individuals (p<0.0001). Notably, for symptomatic individuals, time from symptom onset to testing did not vary by vaccination status. Both vaccinated and unvaccinated individuals in our population reported a median time of 2.4 days between symptom onset and testing. 92% of individuals in our dataset sought testing within 6 days of symptom onset. Together these results suggest that our observations are 155 not confounded by biases in test-seeking behavior between vaccinated and unvaccinated persons (Two-sided K-S test: p=0.0012; medians 2.40d unvaccinated, 2.42d vaccinated, Supplemental Figure 3).

Table 1: Vaccinated vs. Unvaccinated

	Means	95% CI	Effect size d	p-value
Unvaccinated (N=11,084)	22.9	22.8-23.0	0.14	<0.0001
Vaccinated (N=9,347)	22.1	22.0-23.2		

Interpretation of effect size d: (d<0.2 no difference/negligible difference, 0.2-0.5 small difference, 0.5-0.8 moder-164 ate difference, >0.8 large difference) 165

Individuals infected with SARS-CoV-2 despite vaccination shed infectious virus.

Previous studies focusing primarily on unvaccinated individuals suggested that RT-qPCR Ct values <25 may be strongly associated with the shedding of infectious SARS-CoV-2 [8,9]. To determine whether vaccinated persons with potentially high viral burdens might be capable of shedding infectious virus, we inoculated a subset of residual specimens with Ct values <25 onto a monolayer of Vero E6/TMPRSS2 cells and monitored for the presence of cytopathic effects over 5 days. Specimens were selected by N1 Ct-matching between fully vaccinated and unvaccinated persons. Specimens from individuals with unknown vaccine status were excluded from this assay. 37 of 39 specimens from vaccinated individuals contained culturable SARS-CoV-2, as compared with 15 of 17 specimens from unvaccinated persons (Supplemental Figure 4). We therefore performed virus titration on a second set of samples with Ct < 25 and found no difference in infectious virus titer between samples from vaccinated vs. unvaccinated individuals (**Figure 1C**).

178 Ct value in breakthrough infection is not strongly affected by vaccine product, 179 age, or sex.

We considered whether different vaccine products affected Ct values observed in individuals with breakthrough infections. Vaccination had neglible effects on mean Cts in vaccinated as compared with unvaccinated individuals, regardless of the manufacturer, (Janssen (JNJ-78436735) effect size *d*=0.18, p<0.0001; Moderna (mRNA-1273) effect size *d*=0.07, p=0.0052; Pfizer (BNT162b2) effect size *d*=0.17, p<0.0001; **Supplemental Figure 5A**; see also **Supplemental Table 1**). Low-Ct samples were found in similar proportions among all groups, Janssen 68% Ct<25, Moderna 64% Ct<25 and Pfizer 68% Ct<25.

Vaccine effectiveness, particularly against symptomatic, test-positive SARS-CoV-2 infection, wanes with time after vaccine receipt [10–21]. We therefore asked whether Ct values decreased as a function of time between last vaccination and the time at which individuals tested positive for SARS-CoV-2 infection. Indeed, when considering all vaccine products combined, there was a small, but statistically significant decrease in Ct values (consistent with higher levels of SARS-CoV-2 RNA in swab specimens) as the time between last vaccination and positive test increased (Slope: -0.18, 95% CI: -0.26 - 0.10; p-value<0.0001; **Supplemental Figure 5B**). However, when we stratify individuals according to vaccine product received, we find that this effect seems to be driven principally by high Ct values among Pfizer vaccine recipients infected in the first month after vaccination, as the slopes of Ct value vs time between vaccination and infection are not significantly different from zero for recipients of the other two products (**Supplemental Figure 5B**).

Age and male sex have been considered risk factors for COVID-19 disease [22–26]. While one might hypothesize that older individuals and/or males might have higher SARS-CoV-2 burdens and therefore lower Ct values at the time of testing, evidence for this is mixed, with some studies reporting lower Ct values in older individuals [24,27], others in younger individuals [28], and still others finding no difference by age [20,29–34]. We therefore stratified groups based on age and compared Ct values by age group. Vaccination status had negligible effects on Ct values (*d*<0.2) for all age groups considered except those aged 0-11 years (**Supplemental Table 2**). In this group, there were very few vaccinated individuals (N=7), as would be expected because vaccines had not been approved for those 11 and under for most of our study period. Therefore, despite the significant effect size (*d*=0.79, p=0.0466), we do not believe our data strongly support the notion that vaccination status has a strong effect on Ct value in children under 12. When comparing Ct values between unvaccinated and vaccinated within males and females, negligible differences were observed (female: *d*=0.14, male: *d*=0.15; **Supplemental Table 3**).

Discussion

The emergence of Delta variants in the United States led to the first wave of increasing case burdens following the widespread availability of SARS-CoV-2 vaccines. At the time, prevailing public health recommendations were that vaccinated persons need not use face coverings in indoor settings. These recommendations were based in part on the fact that vaccines demonstrated remarkable effectiveness against test-positive SARS-CoV-2 infection in initial clinical trials conducted in 2020 [35-40], suggesting that vaccinated persons might play negligible roles in SARS-CoV-2 transmission. However, the initial vaccine effectiveness studies were conducted when ancestral variants predominated, prior to the emergence of variants of concern. Here we conducted a comprehensive retrospective analysis of RT-PCR Ct values in persons infected with SARS-CoV-2 during the time when Delta variants predominated, to determine whether individuals infected with Delta variants despite vaccination could be involved in community spread of SARS-CoV-2. Combined with other studies [41,42] our data indicate that vaccinated as well as unvaccinated individuals infected with SARS-CoV-2 Delta variants can shed, and potentially transmit, infectious virus [43,44]. We find low Ct values in substantial proportions of both unvaccinated and vaccinated individuals who tested positive for SARS-CoV-2 during the time when Delta variants predominated, in agreement with other recent reports [41,44–47]. The occurrence in our dataset of positive samples from multiple Wisconsin counties without a linking outbreak (more than 80% of samples were not associated with an outbreak known to public health) indicate that Delta-lineage SARS-CoV-2 can achieve low Ct values consistent with transmissibility in fully vaccinated individuals across a range of environments. Importantly, we also show that infectious SARS-CoV-2 is found at similar titers in vaccinated and unvaccinated persons.

An important limitation of our study is that we analyzed only single specimens from each infected individual, so our data cannot determine whether vaccinated individuals control virus replication in the upper respiratory tract more quickly than unvaccinated persons, as other studies have suggested [42]. We also note that the duration and level of infectious virus shedding varies widely among individuals [48], and that Ct values are an imperfect proxy for shedding of infectious virus. However, the vast majority of individuals included in our study were tested within 6 days of symptom onset (**Supplemental Figure 3**), a time before viral loads diverged in vaccinated and unvaccinated persons tested daily in a previous study [42]. Our cross-sectional, laboratory-based study was also not designed to detect or quantify differences in the relative roles of vaccinated and unvaccinated persons in spreading SARS-CoV-2 in the community.

We find that a substantial proportion of individuals infected with Delta viruses despite vaccination had low Ct values consistent with the potential to shed infectious virus. Our findings support the notion that persons infected despite vaccination can transmit SARS-CoV-2. Therefore, preventing infection is critical to preventing transmission. Vaccinated and unvaccinated persons should be tested when symptomatic or after close contact with someone with suspected or confirmed COVID-19. Continued adherence to non-pharmaceutical interventions during periods of high community transmission to mitigate spread of COVID-19 remains important for both vaccinated and unvaccinated individuals.




Figure 1. Individuals infected with SARS-CoV-2 despite full vaccination have low Ct values and shed similar amounts of infectious virus as unvaccinated individuals. A. N1 Ct values for SARS-CoV-2-positive specimens were grouped by vaccination status. RT-PCR was performed by Exact Sciences Corporation, responsible for over 10% of all PCR tests in Wisconsin during this period, using a qualitative diagnostic assay targeting the SARS-CoV-2 N gene (oligonucleotides identical to CDC's N1 primer and probe set) that has been authorized for emergency use by FDA (https://www.fda.gov/media/138328/download). See also Table 1. An effect size of d < 0.2 is negligible. The number of samples in each group is listed under the dot plot. B. N1 Ct values for SARS-CoV-2-positive specimens grouped by vaccination status for individuals who were symptomatic or either asymptomatic or did not have any information, at the time of testing. Light yellow box indicates Ct values <25. C. We

performed plaque assays on Vero E6 TMPRSS2 cells on a subset of specimens. Specimens were selected by N1 Ct-matching between fully vaccinated and unvaccinated persons. Specimens from individuals with unknown vaccination status were excluded from the analysis. Infectious titers are expressed as plaque-forming units (PFU) per milliliter of specimen. Specimens underwent a freeze-thaw cycle prior to virus titration.

Supplemental materials

Supplemental Table 1: Comparisons between vaccine type

299		Mean	95% CI	p-	p-	p-	p-	p-	p-	p-
				value±	value ¹	value ²	value ³	value⁴	value⁵	value ⁶
300	Unvaccinated	22.9	22.8-23.0	<0.0001	<0.0001	0.0052	<0.0001	0.0064	0.9870	0.0001
301	Janssen	21.9	21.6-22.2							
302	Moderna	22.5	22.3-22.7							
303	Pfizer	22.0	21.8-22.1							

[‡] comparisons between all groups

298

304

307

308

311

312

321

322

323324325326

327

328

329


- 305 1: comparison Unvaccinated vs. Janssen (adjusted for multiple comparisons using Tukey's HSD method)
- 306 ²: comparison Unvaccinated vs. Moderna (adjusted for multiple comparisons using Tukey's HSD method)
 - 3: comparison Unvaccinated vs. Pfizer (adjusted for multiple comparisons using Tukey's HSD method)
 - 4: comparison Janssen vs. Moderna (adjusted for multiple comparisons using Tukey's HSD method)
- 309 5: comparison Janssen vs. Pfizer (adjusted for multiple comparisons using Tukey's HSD method)
- 310 ⁶: comparison Moderna vs. Pfizer (adjusted for multiple comparisons using Tukey's HSD method)

Supplemental Table 2: Comparison of Ct values in vaccinated and unvaccinated persons, stratified by age group (there is a significant interaction between age group and vaccination status, p<0.0001)

314	Not Vaccinated		Vaco	inated			
315		Mean	95% CI	Mean	95% CI	Effect size d	p-value
316	0-11 yr	23.9	23.7-24.1	19.8	16.5-23.8	0.79	0.0466
317	12-18 yr	23.0	22.8-23.3	23.9	22.5-23.5	0.00	0.9242
318	19-35 yr	22.4	22.2-22.6	23.0	22.1-22.6	0.00	0.8846
319	36-60 yr	22.3	22.1-22.5	21.9	21.8-22.1	0.07	0.0080
320	>61 yr	22.3	21.9-22.8	22.1	21.8-22.3	0.05	0.3239


Supplemental Table 3: Comparison of Ct values in vaccinated and unvaccinated persons, stratified by sex.

	Unvaccinated		Vacc	inated		
	Mean	95% CI	Mean	95% CI	Effect size d	p-value
Female	23.0	22.9-23.2	22.3	22.1-22.4	0.14	<0.0001
Male	22.8	22.6-22.9	22.0	21.8-22.1	0.15	<0.0001




Supplemental Figure 1. Concordance between self-reported vaccination status and records in public health vaccine registries. Individuals were considered fully vaccinated based on vaccine registry (WIR/WEDSS) data if the registries indicated receipt of a final vaccine dose at least 14 days prior to submitting the sample used in our analysis. For individuals whose vaccination status could not be verified in the registry, self-reported data collected at the time of testing were used. Individuals were considered unvaccinated based on self-report only if there was an explicit declaration of unvaccinated status in the self-reported data. Individuals were considered fully vaccinated based on self-report if they fulfilled all of the following criteria: (1) indicated that they had received a COVID vaccine prior to testing; (2) indicated that they did not require another vaccine dose; and (3) reported a date of last vaccine dose that was at least 14 days prior to testing.


Specimens lacking data on vaccination status were excluded from the study. Specimens from partially vaccinated individuals (incomplete vaccine series, or <14 days post-final dose) were also excluded. Specimens from individuals who received a booster prior to sample collection were also excluded as non-equivalent to those fulfilling the criteria to be considered fully vaccinated. **A.** Of 20,431 specimens with vaccination status available from at least one source, 5,078 specimens had data available from both sources. Under-reporting of full vaccination status in self-reports 1,064/6,142 or 17%) was more common than over-reporting (409/5,487 or 7.4%). **B.** N1 Ct values for SARS-CoV-2-positive specimens grouped by vaccination status for individuals whose vaccination status was determined by vaccine registry or by self-reported data.




Supplemental Figure 2. Log transformation of raw Ct values results in normally distributed residuals. Raw Ct values were not normally distributed, so we log-transformed all Ct values prior to ANOVA, and confirmed normality by plotting residuals and normal probability.



Supplemental Figure 3. Density distributions of unvaccinated and vaccinated specimen collection dates by day since symptom onset. Day 0 on the x-axis denotes self-reported day of symptom onset. Negative values for days indicate specimen collection prior to symptom onset. Symptom onset data were available for n=6,871 unvaccinated cases and n=5,522 vaccinated cases. Two-sided K-S test: p=0.0012; median days since symptom onset were 2.4 for both unvaccinated and vaccinated cases.



Supplemental Figure 4. Infectious SARS-CoV-2 detected in the majority of fully vaccinated individuals with low Ct values. Infectiousness was determined for a subset of N1 Ct-matched specimens with Ct <25 by inoculation onto Vero E6 TMPRSS2 cells, then determining presence or absence of cytopathic effects (CPE) after 5 days in culture. Specimens with unknown vaccination status were excluded from the analysis. Circles indicate presence of CPE; 'X' indicates no CPE detected.



Supplemental Figure 5. Ct values do not differ substantially by vaccine type. A. Comparison of mean N1 Ct values in all specimens, stratified by vaccine type shows negligible effect (d < 0.2) of vaccine type on Ct value at time of positive test, relative to unvaccinated persons. **B.** The time analysis showed a decrease in N1 Ct values with time over 7 months. Combining all three vaccines, there was a significant decrease over the first 7 months, with a slope of -0.18 (95% CI: -0.26 - 0.10), p value <0.0001. Individually, Janssen had a slope -0.19 (95% CI: -0.38 to -0.001, p-value=0.060), Moderna had a slope of -0.13 (95% CI: -0.28 - 0.02, p-value=0.092), Pfizer had a slope of -0.24 (95% CI: -0.24 to -0.13, p-value<0.0001).

468 Conflict of interest

The authors declare no conflicting interests.

570 Ethics statement

- The University of Wisconsin-Madison Institutional Review Board deemed that this project qualifies as public
- health surveillance activities as defined in the Common Rule, 45 CFR 46.102(I)(2). As such, the project is not
- deemed to be research regulated under the Common Rule and therefore, does not require University of Wiscon-
- 474 sin-Madison IRB review and oversight.
- The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Cen-
- ters for Disease Control and Prevention or the institutions with which the authors are affiliated.

Data availability

- Data and processing workflows are available at https://go.wisc.edu/p22/16. To protect potentially personally
- identifiable information, the publicly available dataset contains only PCR Ct values, vaccine status, age, sex,
- manufacturer, symptom status, virus culture status, and days from symptom onset to testing for each specimen.

482 References

- 1. Christie A, Henley SJ, Mattocks L, Fernando R, Lansky A, Ahmad FB, et al. Decreases in COVID-19 Cases,
- Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Intro-
- duction of COVID-19 Vaccine United States, September 6, 2020-May 1, 2021. Morbidity and Mortality
- 486 Weekly Report. 2021;70: 858–864.
- 487 2. Alagoz O, Sethi AK, Patterson BW, Churpek M, Alhanaee G, Scaria E, et al. The impact of vaccination
- to control COVID-19 burden in the United States: A simulation modeling approach. PLoS One. 2021;16:
- 489 **e0254456**.
- 490 3. Borchering RK, Viboud C, Howerton E, Smith CP, Truelove S, Runge MC, et al. Modeling of Future COVID-19
- Cases, Hospitalizations, and Deaths, by Vaccination Rates and Nonpharmaceutical Intervention Scenarios -
- United States, April-September 2021. MMWR Morb Mortal Wkly Rep. 2021;70: 719–724.
- 493 4. Shitrit P, Zuckerman NS, Mor O, Gottesman B-S, Chowers M. Nosocomial outbreak caused by the
- SARS-CoV-2 Delta variant in a highly vaccinated population, Israel, July 2021. Euro Surveill. 2021;26.
- doi:10.2807/1560-7917.ES.2021.26.39.2100822
- 496 5. Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwels KB, et al. Effect of Covid-19 Vaccination on
- Transmission of Alpha and Delta Variants. N Engl J Med. 2022;386: 744–756.
- 498 6. Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer; 2016.
- 499 7. Zupin L, Fontana F, Clemente L, Ruscio M, Crovella S. Comparison between nucleic acid amplification
- tests, antigen immunofluorescence assay, and in vitro infectivity in SARS-CoV-2 diagnosis. Braz J Microbiol.
- 501 2022. doi:10.1007/s42770-022-00758-6
- 502 8. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2
- Infections and Transmission in a Skilled Nursing Facility. N Engl J Med. 2020. doi:10.1056/NEJMoa2008457
- 504 9. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of
- hospitalized patients with COVID-2019. Nature. 2020;581: 465–469.
- 506 10. Oda G, Sharma A, Lucero-Obusan C, Schirmer P, Sohoni P, Holodniy M. COVID-19 Infections Among
- Healthcare Personnel in the United States Veterans Health Administration, March to August, 2020. J Occup
- 508 Environ Med. 2021;63: 291–295.
- 509 11. Sharma A, Oda G, Holodniy M. COVID-19 vaccine breakthrough infections in Veterans Health Administra-
- tion. bioRxiv. 2021. doi:10.1101/2021.09.23.21263864
- 12. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical severity of, and ef-
- fectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the
- United States: prospective observational study. BMJ. 2022;376: e069761.


- 13. Robles-Fontán MM, Nieves EG, Cardona-Gerena I, Irizarry RA. Effectiveness estimates of three COVID-19 vaccines based on observational data from Puerto Rico. Lancet Reg Health Am. 2022;9: 100212.
- 14. Terpos E, Karalis V, Ntanasis-Stathopoulos I, Evangelakou Z, Gavriatopoulou M, Manola MS, et al. Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222.

 Biomedicines. 2022;10. doi:10.3390/biomedicines10020338
- 519 15. Sughayer MA, Souan L, Abu Alhowr MM, Al Rimawi D, Siag M, Albadr S, et al. Comparison of the effective-520 ness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: 521 Implications for vaccine strategies. Vaccine. 2022;40: 2841–2847.
- 16. Magalis BR, Mavian C, Tagliamonte M, Rich SN, Cash M, Riva A, et al. Low-frequency variants in mildly symptomatic vaccine breakthrough infections presents a doubled-edged sword. J Med Virol. 2022. doi:10.1002/jmv.27726
- 17. Lin D-Y, Gu Y, Wheeler B, Young H, Holloway S, Sunny S-K, et al. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. N Engl J Med. 2022;386: 933–941.
- 18. Bonnet B, Chabrolles H, Archimbaud C, Brebion A, Cosme J, Dutheil F, et al. Decline of Humoral and Cellular Immune Responses Against SARS-CoV-2 6 Months After Full BNT162b2 Vaccination in Hospital Healthcare Workers. Front Immunol. 2022;13: 842912.
- 19. Burns MD, Boribong BP, Bartsch YC, Loiselle M, St Denis KJ, Sheehan ML, et al. Durability and Cross-Reactivity of SARS-CoV-2 mRNA Vaccine in Adolescent Children. Vaccines (Basel). 2022;10. doi:10.3390/ vaccines10040492
- 533 20. Sanna G, Marongiu A, Firinu D, Piras C, Franci G, Galdiero M, et al. Neutralizing Antibodies Responses 534 against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination. Vaccines 535 (Basel). 2022;10. doi:10.3390/vaccines10040531
- Tartof SY, Slezak JM, Puzniak L, Hong V, Xie F, Ackerson BK, et al. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study. Lancet Respir Med. 2022. doi:10.1016/S2213-2600(22)00101-1
- 540 22. Shapiro JR, Park H-S, Aytenfisu TY, Caputo C, Lee J, Johnston TS, et al. Association of frailty, age, and 541 biological sex with SARS-CoV-2 mRNA vaccine-induced immunity in older adults. medRxiv. 2022. Available: 542 https://pubmed.ncbi.nlm.nih.gov/35607747
- Molani S, Hernandez PV, Roper RT, Duvvuri VR, Baumgartner AM, Goldman JD, et al. Risk factors for severe COVID-19 differ by age for hospitalized adults. Sci Rep. 2022;12: 6568.
- Heald-Sargent T, Muller WJ, Zheng X, Rippe J, Patel AB, Kociolek LK. Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to

- Moderate Coronavirus Disease 2019 (COVID-19). JAMA Pediatr. 2020;174: 902–903.
- 548 25. Heald AH, Jenkins DA, Williams R, Sperrin M, Mudaliar RN, Syed A, et al. Mortality in People with Type 2
 549 Diabetes Following SARS-CoV-2 Infection: A Population Level Analysis of Potential Risk Factors. Diabetes
 550 Ther. 2022;13: 1037–1051.
- 26. Chen U-I, Xu H, Krause TM, Greenberg R, Dong X, Jiang X. Factors Associated With COVID-19 Death in the United States: Cohort Study. JMIR Public Health Surveill. 2022;8: e29343.
- Euser S, Aronson S, Manders I, van Lelyveld S, Herpers B, Sinnige J, et al. SARS-CoV-2 viral-load distribution reveals that viral loads increase with age: a retrospective cross-sectional cohort study. Int J Epidemiol. 2022;50: 1795–1803.
- Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, et al. Duration of infectiousness and
 correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro
 Surveill. 2020;25. doi:10.2807/1560-7917.ES.2020.25.32.2001483
- Jones TC, Mühlemann B, Veith T, Biele G, Zuchowski M, Hofmann J, et al. An analysis of SARS-CoV-2 viral
 load by patient age. bioRxiv. medRxiv; 2020. doi:10.1101/2020.06.08.20125484
- 30. Maltezou HC, Magaziotou I, Dedoukou X, Eleftheriou E, Raftopoulos V, Michos A, et al. Children and Adolescents With SARS-CoV-2 Infection: Epidemiology, Clinical Course and Viral Loads. Pediatr Infect Dis J. 2020;39: e388–e392.
- 31. Mahallawi WH, Alsamiri AD, Dabbour AF, Alsaeedi H, Al-Zalabani AH. Association of Viral Load in SARS-CoV-2 Patients With Age and Gender. Front Med. 2021;8: 608215.
- 566 32. Penney J, Jung A, Koethe B, Doron S. Cycle threshold values and SARS-CoV-2: Relationship to demo-567 graphic characteristics and disease severity. J Med Virol. 2022. doi:10.1002/jmv.27752
- 568 33. Yonker LM, Boucau J, Regan J, Choudhary MC, Burns MD, Young N, et al. Virologic Features of Severe 569 Acute Respiratory Syndrome Coronavirus 2 Infection in Children. J Infect Dis. 2021;224: 1821–1829.
- 570 34. Lieberman NAP, Peddu V, Xie H, Shrestha L, Huang M-L, Mears MC, et al. In vivo antiviral host transcrip-571 tional response to SARS-CoV-2 by viral load, sex, and age. PLoS Biol. 2020;18: e3000849.
- 572 35. Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim Results of a Phase 573 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021;384: 1824–1835.
- 36. Sa S, Lee CW, Shim SR, Yoo H, Choi J, Kim JH, et al. The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data. Vaccines (Basel). 2022;10. doi:10.3390/vaccines10020320
- 577 37. Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of effectiveness 578 of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and me-

ta-regression. Lancet. 2022;399: 924–944.

- 38. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2 Preliminary Report. N Engl J Med. 2020;383: 1920–1931.
- 39. Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et al. Immune correlates analysis
 of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2021; eab3435.
- Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020;383: 2439–2450.
- 586 41. Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta K-D, et al. Effect of Delta variant on 587 viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med. 2021;27: 588 2127–2135.
- 589 42. Chia PY, Ong SWX, Chiew CJ, Ang LW, Chavatte J-M, Mak T-M, et al. Virological and serological kinetics of 590 SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Clin Microbiol Infect. 591 2022;28: 612.e1–612.e7.
- 592 43. Siedner MJ, Boucau J, Gilbert RF, Uddin R, Luu J, Haneuse S, et al. Duration of viral shedding and culture 593 positivity with postvaccination SARS-CoV-2 delta variant infections. JCI Insight. 2022;7. doi:10.1172/jci. 594 insight.155483
- 595 44. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. Covid-19 Breakthrough Infections in 596 Vaccinated Health Care Workers. N Engl J Med. 2021;385: 1474–1484.
- 597 45. SriramanAK, ShaikhA, Vaswani S, Mestry T, Patel G, Sakthivel S, et al. Impact of Delta and Vaccination on SARS-598 CoV- transmission risk: Lessons for Emerging Breakthrough infections. doi:10.1101/2022.03.02.22271385
- Kislaya I, Peralta-Santos A, Borges V, Vieira L, Sousa C, Ferreira B, et al. Comparative complete scheme
 and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2
 Omicron (BA.1) and Delta (B.1.617.2) variants. bioRxiv. 2022. doi:10.1101/2022.01.31.22270200
- Kissler SM, Fauver JR, Mack C, Tai CG, Breban MI, Watkins AE, et al. Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons. N Engl J Med. 2021;385: 2489–2491.
- 48. Ke R, Martinez PP, Smith RL, Gibson LL, Mirza A, Conte M, et al. Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. Nature Microbiology. 2022; 1–13.



unvaccinated vaccinated unvaccinated vaccinated unvaccinated vaccinated